BioSpace News Archive

Global Blood Therapeutics, Inc. announced results from the Sickle Cell Health Awareness, Perspectives and Experiences survey, a multinational survey on the burden of sickle cell disease and unmet needs as reported by more than 1,300 patients, caregivers and healthcare professionals in 10 countries.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience held virtually June 10-12, 2022.

Onconova Therapeutics, Inc. today announced that Mark Guerin was appointed Chief Operating Officer in addition to his current role as Onconova’s Chief Financial Officer (CFO), and that Dr. Adar Makovski Silverstein was appointed Senior Director and Head of Corporate Development.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced positive Phase 2b data of encaleret in patients with autosomal dominant hypocalcemia type 1.

Mustang Bio, Inc. announced that updated interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, show a favorable safety profile, high overall response and complete response rates, and CAR T persistence in patients with follicular lymphoma.

Homology Medicines, Inc., a genetic medicines company, announced that the U.S. Food and Drug Administration lifted the clinical hold previously placed on the pheNIX gene therapy clinical trial with investigational HMI-102 for adults with phenylketonuria.

NightHawk Biosciences announced the appointment of Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services.

Hillstream BioPharma, Inc. announced that its Board of Directors has authorized a share repurchase program to acquire up to $1 million of the Company’s common stock.

Daxor Corporation announces it will exhibit at the American Association of Heart Failure Nurses 18th Annual Meeting from June 15-18th, 2022 at the Rosen Shingle Creek Resort in Orlando, Florida.

AIM ImmunoTech Inc. announced that the Netherlands Patent Office has issued Patent No. 2027383 — a utility patent — covering Ampligen® and other AIM developed dsRNA products for use in the prevention or treatment of COVID-19, with a base patent term extending until 2041.